GLP-1 Market
LLY $1431.67 ▼ -0.8% NVO $41.60 ▼ -0.1% PFE $28.86 ▼ -0.1% VKTX $26.80 ▼ -8.3% KLRA $12.57 ▼ -5.3% GPCR $18.57 ▼ -7.2% RHHBY $60.95 ▲ +1.1%
Market data delayed up to 20 min · Source: Twelve Data
About this data Sourced primarily from ClinicalTrials.gov — a listing isn't proof of safety or FDA approval.

Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.

Not yet reported

Inclisiran sodium (equivalent to inclisiran) in

Company
Duke University
Mechanism
Mechanism not yet reported
Route
Route not yet reported
Recruiting trials
9 recruiting

Efficacy results: Not yet reported

Find a Clinical Trial Near Me

9 recruiting studies currently listed on ClinicalTrials.gov.

Data source: ClinicalTrials.gov · trial data as of Nov 17, 2026

Find a Clinical Trial Near Me

See recruiting studies for Inclisiran sodium (equivalent to inclisiran) in and check eligibility with the study team.

Select conditions
Match
Treatment type

"Added to GLP-1" means the investigational treatment is being studied on top of an existing GLP-1-based therapy.

Your ZIP code is only used to calculate distance to trial sites — it isn't stored.

Trial details
  • Recruiting NCT NCT05682378

    Long-term Safety and Tolerability of Inclisiran in Participants With HeFH or HoFH Who Have Completed the Pediatric ORION-16, ORION-13, ORION-20, or ORION-19 Studies

    Not yet reported Novartis Pharmaceuticals 195 participants Est. completion 2032-03-28 52 sites
    Other conditions: Heterozygous or Homozygous Familial Hypercholesterolemia
    View official trial listing →
  • Recruiting NCT NCT06501443

    LATAM LOWERS LDL-C

    Not yet reported Novartis Pharmaceuticals 520 participants Est. completion 2026-11-29 11 sites Stand-alone
    Other conditions: Hypercholesterolaemia
    View official trial listing →
  • Recruiting NCT NCT06597006

    Study to Evaluate Safety, Tolerability and Efficacy of Inclisiran in Children With Homozygous Familial Hypercholesterolemia

    Not yet reported Novartis Pharmaceuticals 9 participants Est. completion 2029-04-15 19 sites
    Other conditions: Familial Hypercholesterolemia - Homozygous
    View official trial listing →
  • Recruiting NCT NCT06597019

    Study to Evaluate Efficacy and Safety of Inclisiran in Children With Heterozygous Familial Hypercholesterolemia

    Not yet reported Novartis Pharmaceuticals 60 participants Est. completion 2029-04-15 66 sites
    Other conditions: Familial Hypercholesterolemia - Heterozygous
    View official trial listing →
  • Recruiting NCT NCT06865885

    LDL-C Optimization Using Inclisiran in Patients in Which Drug-Drug Interactions Limit LDL Lowering

    Not yet reported University of California, San Diego 100 participants Est. completion 2028-09-01 1 site
    Metabolic syndrome Other conditions: Drug Interactions, Primary Prevention, LDL-Cholersterol Lowering, Polypharmacy
    View official trial listing →
  • Recruiting NCT NCT06909565

    Inclisiran Versus Placebo for the Prevention of Major Adverse Cardiovascular and Limb Events in Patients Undergoing Percutaneous Coronary Intervention or Peripheral Endovascular Intervention

    Not yet reported Duke University 6000 participants Est. completion 2029-12 153 sites
    Other conditions: Percutaneous Coronary Intervention, Peripheral Endovascular Intervention
    View official trial listing →
  • Recruiting NCT NCT07102628

    Evaluation of Efficacy and Safety of Early in Hospital Initiation of Inclisiran Treatment in Patients With Acute Coronary Syndromes

    Not yet reported Novartis Pharmaceuticals 300 participants Est. completion 2027-02-11 69 sites Stand-alone
    Other conditions: Acute Coronary Syndrome
    View official trial listing →
  • Recruiting NCT NCT07610278

    A Study to Evaluate the Pharmacodynamics of a Combination of QCZ484 and Inclisiran in Participants With Hypertension and Concomitant Hypercholesterolemia

    Not yet reported Novartis Pharmaceuticals 120 participants Est. completion 2028-02-03 29 sites
    Other conditions: Hypercholesterolaemia
    View official trial listing →
  • Recruiting NCT NCT07626281

    Assessment of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of a New Formulation of Inclisiran Containing Polysorbate 80 Compared to the Currently Marketed Formulation

    Not yet reported Novartis Pharmaceuticals 152 participants Est. completion 2026-12-21 6 sites
    Other conditions: Inclisiran Formulation
    View official trial listing →
  • Completed NCT NCT03851705

    A Study of Inclisiran in Participants With Homozygous Familial Hypercholesterolemia (HoFH)

    Not yet reported Novartis Pharmaceuticals 56 participants Est. completion 2021-09-09 13 sites
    Other conditions: Homozygous Familial Hypercholesterolemia
    View official trial listing →
  • Completed NCT NCT04652726

    Study to Evaluate Efficacy and Safety of Inclisiran in Adolescents With Heterozygous Familial Hypercholesterolemia

    Not yet reported Novartis Pharmaceuticals 141 participants Est. completion 2024-11-27 59 sites Stand-alone
    Other conditions: Familial Hypercholesterolemia - Heterozygous
    View official trial listing →
  • Completed NCT NCT04659863

    Study to Evaluate Efficacy and Safety of Inclisiran in Adolescents With Homozygous Familial Hypercholesterolemia

    Not yet reported Novartis Pharmaceuticals 13 participants Est. completion 2024-11-18 11 sites Stand-alone
    Other conditions: Familial Hypercholesterolemia - Homozygous
    View official trial listing →
  • Completed NCT NCT04666298

    Study of Efficacy and Safety of Inclisiran in Japanese Participants With High Cardiovascular Risk and Elevated LDL-C

    Not yet reported Novartis Pharmaceuticals 312 participants Est. completion 2022-10-19 42 sites
    Other conditions: Hypercholesterolemia, Heterozygous Familial Hypercholesterolemia
    View official trial listing →
  • Active, not recruiting NCT NCT04765657

    Study of Efficacy and Safety of Inclisiran in Asian Participants With Atherosclerotic Cardiovascular Disease (ASCVD) or ASCVD High Risk and Elevated Low Density Lipoprotein Cholesterol (LDL-C)

    Not yet reported Novartis Pharmaceuticals 345 participants Est. completion 2026-12-28 45 sites
    Other conditions: Hypercholesterolemia
    View official trial listing →
  • Completed NCT NCT04774003

    Study of Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Inclisiran in Chinese Participants With Elevated Serum LDL-C

    Not yet reported Novartis Pharmaceuticals 40 participants Est. completion 2021-10-18 3 sites
    Other conditions: Hyperlipidemia
    View official trial listing →
  • Completed NCT NCT04873934

    Management of LDL-cholesterol With Inclisiran + Usual Care Compared to Usual Care Alone in Participants With a Recent Acute Coronary Syndrome

    Not yet reported Novartis Pharmaceuticals 400 participants Est. completion 2024-08-07 88 sites
    Other conditions: Acute Coronary Syndrome
    View official trial listing →
  • Active, not recruiting NCT NCT05030428

    Study of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease

    Not yet reported Novartis Pharmaceuticals 17004 participants Est. completion 2027-05-10 989 sites
    Cardiovascular disease
    View official trial listing →
  • Completed NCT NCT05192941

    Study of Efficacy, Safety, Tolerability and Quality of Life of Inclisiran (KJX839) vs Placebo, on Top of Ongoing Individually Optimized Lipid-lowering Therapy, in Participants With Hypercholesterolemia

    Not yet reported Novartis Pharmaceuticals 1770 participants Est. completion 2025-03-19 136 sites
    Other conditions: Hypercholesterolemia
    View official trial listing →
  • Active, not recruiting NCT NCT05360446

    Coronary Computed Tomography Study to Assess the Effect of Inclisiran in Addition to Maximally Tolerated Statin Therapy on Atherosclerotic Plaque Progression in Participants With a Diagnosis of Non-obstructive Coronary Artery Disease Without Previous Cardiovascular Events

    Not yet reported Novartis Pharmaceuticals 610 participants Est. completion 2026-10-27 89 sites
    Cardiovascular disease
    View official trial listing →
  • Active, not recruiting NCT NCT05739383

    A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.

    Not yet reported Novartis Pharmaceuticals 14012 participants Est. completion 2029-04-16 983 sites Stand-alone
    Cardiovascular disease
    View official trial listing →
  • Completed NCT NCT05763875

    Efficacy and Safety of Inclisiran as Monotherapy in Patients With Primary Hypercholesterolemia Not Receiving Lipid-lowering Therapy.

    Not yet reported Novartis Pharmaceuticals 350 participants Est. completion 2024-06-20 42 sites
    Other conditions: Hypercholesterolemia
    View official trial listing →
  • Completed NCT NCT05888103

    Efficacy and Safety of Inclisiran as Monotherapy in Chinese Adults With Low or Moderate ASCVD Risk and Elevated Low-density Lipoprotein Cholesterol.

    Not yet reported Novartis Pharmaceuticals 207 participants Est. completion 2024-10-24 28 sites
    Other conditions: Primary Hypercholesterolemia or Mixed Dyslipidemia
    View official trial listing →
  • Completed NCT NCT05974345

    In Silico Study Assessing the Impact of Inclisiran on Major Adverse Cardiovascular Events in Patients With Established Cardiovascular Disease

    Novartis Pharmaceuticals 204691 participants Est. completion 2023-12-15 1 site
    Cardiovascular disease
    View official trial listing →
  • Completed NCT NCT06386419

    A Clinical Study to Evaluate the Safety and Effectiveness of Inclisiran Sodium in Indian Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia

    Not yet reported Novartis Pharmaceuticals 65 participants Est. completion 2026-01-13 9 sites
    Other conditions: Primary Hypercholesterolemia, Mixed Dyslipidemia
    View official trial listing →
  • Active, not recruiting NCT NCT06958315

    Inclisiran (Leqvio®) in Patients With Atherosclerotic Vascular Disease and/or Heterozygous Familial Hypercholesterolemia Treated in Spain: the INSPIRE Study

    Novartis Pharmaceuticals 219 participants Est. completion 2027-05-01 20 sites
    Other conditions: Atherosclerotic Vascular Disease, Heterozygous Familial Hypercholesterolemia
    View official trial listing →
  • Not yet recruiting NCT NCT07684469

    Comparative Assessment of Inclisiran on Top of Standard of Care Versus Standard of Care Alone for LDL-C Evaluation in Acute Coronary Syndrome Patients in Saudi Arabia

    Not yet reported Novartis Pharmaceuticals 300 participants Est. completion 2029-02-28
    Other conditions: Acute Coronary Syndrome
    View official trial listing →
Efficacy history

Not yet reported.

Safety

Not yet reported.

Sources

Also known as: Inclisiran sodium (equivalent to inclisiran) in, Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL, KJX839

Related On The Pen coverage

No related coverage yet.

This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.